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Shiga toxin ‘goes retro’ in human 
primary kidney cells
JC Paton1 and AW Paton1
The pathway and the efficiency of intracellular trafficking of Shiga 
toxin differ between cell types, and this impacts on susceptibility to 
cytotoxicity. Warnier et al. demonstrate that in cell types targeted during 
human disease, Shiga toxin undergoes retrograde transport via the 
trans-Golgi network to the endoplasmic reticulum, albeit less efficiently 
than in HeLa cells.
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Th e Shiga toxins (Stxs) are a distinct fam-
ily of AB5 cytotoxins produced by certain 
strains of Escherichia coli and related 
enterobacteria. The toxins comprise a 
catalytic A subunit that is an RNA-N-
glycosidase capable of cleaving a critical 
adenine base from 28S ribosomal RNA, 
thereby inhibiting the elongation step of 
eukaryotic protein synthesis. Th e penta-
meric B subunit is responsible for bind-
ing to a specifi c glycolipid receptor (Gb3) 
on the surface of target cells, triggering 
internalization of the receptor–holotoxin 
complex. A landmark study by Karmali et 
al.1 established a causal link between gas-
trointestinal infection with Shiga toxigenic 
E. coli and hemolytic-uremic syndrome, 
a potentially life-threatening condition 
characterized by microangiopathic hemo-
lytic anemia, thrombocytopenia, and 
acute renal failure. Th e primary insult in 
hemolytic-uremic syndrome is Stx-medi-
ated damage to microvascular endothelial 
cells, particularly in the kidney, initiating 
the coagulation cascade.
During Shiga toxigenic E. coli infection, 
Stx released into the gut lumen is translo-
cated across the intestinal epithelium into 
the underlying tissues and bloodstream 
and then targets host cells expressing Gb3. 
In humans, high concentrations of Gb3 are 
found in renal tubular cells and microvas-
cular endothelial cells, particularly those 
in the kidney, gut, and brain, consistent 
with the clinical manifestations of disease. 
Interestingly, not all Gb3-expressing cell 
types are equally susceptible to Stx, and 
it is becoming increasingly apparent that 
differences in toxin trafficking within 
these cells determine the outcome of the 
interaction.
Studies of traffi  cking of Stx in highly 
susceptible immortalized cell lines 
showed that after binding to Gb3, the 
toxin is internalized by receptor-mediated 
endocytosis. Briefl y, this involves the for-
mation of a clathrin-coated pit within the 
cell membrane, which pinches off  to form 
early endosomes, with toxin bound to the 
internal surface. From here it is trans-
ported directly to the trans-Golgi network, 
bypassing late endosomes, and then via 
the Golgi apparatus to the endoplasmic 
reticulum (ER)2 (Figure 1). Th is retro-
grade transport appears to require asso-
ciation of receptor–holotoxin complexes 
with lipid rafts, which are specialized 
membrane microdomains rich in choles-
terol and glycosphingolipids. Association 
of toxin with these raft s may be facilitated 
by the cross-linking of multiple glycolip-
ids by the pentameric B subunit. Th is then 
enables the toxin to exploit the membrane 
recycling pathway within the cell, which is 
essential for retrograde transport. Indeed, 
experimental destabilization of lipid raft s 
by extraction of cholesterol has a severe 
inhibitory eff ect on traffi  cking of Stx from 
early endosomes to the Golgi.3
Once Stx has reached the ER, the cata-
lytic A subunit (StxA) must be trans-
located across the ER membrane, and 
during this step, it is nicked by furin. 
Th e major A1 fragment is subsequently 
released into the cytosol, where it can 
reach its substrate (28S ribosomal RNA) 
and exert its cytotoxic eff ects (Figure 1). 
StxA has no intrinsic capacity to cross 
membranes, and retro-translocation is 
achieved by subversion of another cel-
lular process, in this case the protein-
translocation channel Sec61.4 Sec61 is 
normally used for the secretion of newly 
synthesized proteins, as well as for trans-
port of terminally misfolded host proteins 
from the ER lumen back into the cytosol, 
where they are ubiquitinated and targeted 
to the proteasome for degradation. Retro-
translocation of StxA via Sec61 involves 
interaction with two distinct ER chaper-
ones, BiP and HEDJ/ERdj3, which may 
mistake a hydrophobic domain toward 
the C terminus of StxA for a terminally 
misfolded protein.4 Presumably, retro-
translocated StxA escapes ubiquitination 
and degradation and is then free to inter-
act with 28S ribosomal RNA.
Th e situation is markedly diff erent in 
monocytes/macrophages and related cell 
lines, which express Gb3 on their surface 
and bind Stx, but are not susceptible to 
Stx-induced inhibition of protein synthe-
sis.5 In these cells, bound toxin-receptor 
complexes are internalized into early 
endosomes, but they do not become 
associated with lipid rafts or enter the 
retrograde pathway. Instead they fuse 
with late endosomes and are targeted to 
the lysosomes where the toxin is degraded 
(Figure 1).4 Th is is not to say that Stx has 
no eff ect on monocytes/macrophages. On 
the contrary, Stx is known to activate the 
mitogen-activated protein kinase pathway, 
leading to nuclear translocation of nuclear 
factor-κB and production of cytokines 
such as tumor necrosis factor-α (TNF-
α) and interleukin-6.5,6 Th is may be of 
importance during pathogenesis of Shiga 
toxigenic E. coli disease, because TNF-α 
is known to upregulate Gb3 expression by 
microvascular endothelial cells, sensitizing 
1School of Molecular and Biomedical Science, 
University of Adelaide, Adelaide, Australia
Correspondence: JC Paton, School of Molecular 
and Biomedical Science, University of Adelaide, 
Adelaide, South Australia 5005, Australia. 
E-mail: james.paton@adelaide.edu.au
see original article on page 2085
2050   Kidney International (2006) 70
commentar y
them to Stx. What then determines the 
intracellular fate of Gb3–Stx complexes, 
and as a consequence the extent of cyto-
toxicity/activation? Clearly, association 
with lipid raft s is of pivotal importance, 
and this could be infl uenced by the fatty-
acyl moieties of diff erent Gb3 isoforms. 
Other aspects of gross membrane com-
position — for example, cholesterol and 
glycosphingolipid content — may also be 
important.2,7
Notwithstanding the above, few stud-
ies have directly examined Stx traffi  ck-
ing in cells that are targeted by the toxin 
in hemolytic-uremic syndrome, particu-
larly those in the kidney. Warnier et al.8 
(this issue) have now examined traffi  ck-
ing of StxB in human glomerular micro-
vascular endothelial cells (GMVECs) and 
mesangial cells (MCs). Th ese cell types 
have previously been shown to express 
Gb3 constitutively, and to upregulate 
it further after stimulation with TNF-
α. Nevertheless, whether stimulated or 
not, both cell types were more resistant 
to Stx-mediated cytotoxicity than HeLa 
or Vero cells, although protein synthesis 
was still inhibited.9,10 Warnier et al.8 used 
a combination of immunofl uorescence 
microscopy and biochemical techniques 
to demonstrate defi nitively that StxB does 
indeed undergo retrograde transport to 
the ER in both these primary cell types. 
Cy3-labeled StxB colocalized with the 
Golgi marker CTR433 within 4 hours of 
exposure, but was no longer detectable 
in the Golgi compartment aft er 24 hours. 
Th e authors then used a derivative of StxB 
carrying a tandem sulfation signal recog-
nized by a trans-Golgi network-localized 
sulfotransferase. Th is enabled autoradio-
graphic assessment of retrograde transport 
to the trans-Golgi network compartment 
by exposing GMVECs and MCs to the 
tagged StxB derivative in the presence of 
[35S]sulfate. Arrival in the ER itself was 
confi rmed with the use of a diff erent StxB 
derivative with an N-glycosylation site 
introduced at its C terminus. Th is acted as 
a substrate for ER-localized oligosaccha-
ryl transferase, and glycosylation of StxB 
(and, by inference, arrival in the ER) was 
evident from an electrophoretic mobility 
shift . Pre-labeling of the tagged StxB with 
125I enabled quantitative assessment of the 
extent of glycosylation, which was detect-
able in both GMVECs and MCs and was 
greater aft er 24 hours of incubation than at 
4 hours. Approximately 7%–10% of total 
cell-associated StxB was glycosylated at the 
latter time point in both cell types. In both 
the sulfation and the glycosylation assays, 
the total amount of Stx transported was 
greater in cells that had been pre stimulated 
with TNF-α. However, this was directly 
attributable to increased expression of Gb3 
(and hence the total amount of StxB that 
bound to the cell surface), rather than to 
any eff ect of TNF-α on the effi  ciency of 
retrograde transport.
Interestingly, the close correlation 
between Gb3 expression and the total 
amount of StxB transported to the ER 
did not hold when GMVECs and MCs 
were compared with HeLa cells. Th e lat-
ter transported signifi cantly more StxB to 
the ER compartment, even though total 
Gb3 levels were lower than in TNF-α-
stimulated GMVECs or MCs. Increased 
retrograde transport is also consistent 
with the greater lethality of Stx holotoxin 
previously observed for cancer cell lines 
such as HeLa, compared with the pri-
mary human cells. Why should this be 
so? One possibility is that the various cell 
types express Gb3 isoforms that diff er in 
their capacity to associate with lipid raft s, 
as suggested previously for monocytes/
macrophages versus HeLa cells. How-
ever, Warnier et al.8 report that the total 
amounts of 125I-StxB associating with the 
lipid raft  fraction were similar between the 
three cell types. Th is suggests that there is 
some other fundamental diff erence in the 
effi  ciency of the retrograde traffi  cking sys-
tem, perhaps the rate of vesicle recycling.
Of course, the susceptibility of a given 
cell type to Stx will also be aff ected by the 
efficiency of retro-translocation of the 
catalytic A1 fragment across the ER mem-
brane into the cytosol. Th is will directly 
infl uence the extent of damage infl icted 
on the protein synthesis machinery. A 
recent study11 has shown that association 
of Stx with lipid raft s is important for this 
process as well, and that other membrane 
glycosphingolipids aff ect the partition-
ing of Stx into these functionally critical 
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Figure 1 | Distinct intracellular trafficking pathways for Shiga toxin (Stx) in sensitive and 
insensitive cells.
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ER microdomains. It is noteworthy that 
certain ER proteins involved in the retro-
translocation process also partitioned into 
the lipid raft  fraction. Further studies are 
needed to determine whether there are 
innate diff erences in the effi  ciency of this 
final retro-translocation step between 
primary renal cells, such as GMVECs 
and MCs, and the more susceptible cell 
lines. Deficiency in either retrograde 
transport of Stx from the cell surface to 
the ER, or retro-translocation across the 
ER membrane into the cytosol, is likely 
to result in sublethal amounts of toxic 
StxA1 entering the latter compartment, 
limiting ribosomal damage. In some cell 
types — for example, intestinal epithelial 
cells and human umbilical vein endothe-
lial cells — sublethal toxin doses have 
been shown to elicit a so-called ‘ribotoxic 
stress response,’ which is characterized by 
increased production of new ribo somes 
and proinfl ammatory cytokines.12 Further 
research is needed to determine whether 
similar responses are elicited in renal 
cells such as GMVECs and MCs. This 
will throw further light on the relative 
contribution of direct Stx toxicity versus 
toxin-induced infl ammatory responses to 
the pathophysiology of hemolytic-uremic 
syndrome.
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Comprehensive suppression of the 
renin–angiotensin–aldosterone 
system in chronic kidney disease: 
Covering all of the bases
MH Weinberger1 and FC Luft2
Reducing proteinuria and blood pressure in chronic kidney 
disease (CKD) decreases rate of progression. Inhibition of the renin–
angiotensin system by angiotensin-converting enzyme inhibitors and/
or angiotensin receptor blockers is beneficial in reducing proteinuria 
but incomplete in suppressing aldosterone production and its renal 
effects. Adding aldosterone receptor blockers to these other agents 
may further halt the progression of CKD.
Kidney International (2006) 70, 2051–2053. doi:10.1038/sj.ki.5002007
Chronic kidney disease (CKD) has become 
a health burden of increasing proportions, 
with the numbers of patients continu-
ing to rise despite new pharmacological 
approaches to treatment. Lower blood 
pressure goals have been shown to be of 
great benefi t in slowing or halting the pro-
gression of CKD. A variety of interventions 
directed at inhibition of components of the 
renin–angiotensin system are known to be 
particularly useful. Despite these advances 
in treatment, beginning with the introduc-
tion of angiotensin-converting enzyme 
inhibitors (ACEIs) and, more recently, 
angiotensin receptor blockers (ARBs), the 
burden of CKD has continued to increase. 
Some have suggested a role for aldoster-
one synthesis ‘escape’ from inhibition of 
the renin system in CKD, which has led 
to the use of combination therapy with 
ACEIs plus ARBs to achieve more com-
plete inhibition of the renin–angiotensin–
aldosterone system. Although useful, this 
approach is only modestly eff ective. Per-
haps stimulated by the emerging evidence 
of direct vascular eff ects of aldosterone as 
well as eff ects on the heart and the kidney, 
and by the beneficial effects of adding 
inhibitors of aldosterone, such as spirono-
lactone1 and eplerenone,2 to multiple 
drug therapy in congestive heart failure, 
clinician-investigators have pursued the 
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